Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread
Cancer Medicine · 2024
DOI: 10.1002/cam4.7377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Bowen Xue und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Neoplasm Grading. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
The study aimed to identify if clinical features and survival outcomes of insular glioma patients are associated with our classification based on the tumor spread.
Methods
Our study included 283 consecutive patients diagnosed with histological grade 2 and 3 insular gliomas. A new classification was proposed, and tumors restricted to the paralimbic system were defined as type 1. When tumors invaded the limbic system (referred to as the hippocampus and its surrounding structures in this study) simultaneously, they were defined as type 2. Tumors with additional internal capsule involvement were defined as type 3.
Results
Tumors defined as type 3 had a higher age at diagnosis ( p = 0.002) and a higher preoperative volume ( p < 0.001). Furthermore, type 3 was more likely to be diagnosed as IDH wild type ( p < 0.001), with a higher rate of Ki‐67 index ( p = 0.015) and a lower rate of gross total resection ( p < 0.001). Type 1 had a slower tumor growth rate than type 2 (mean 3.3%/month vs. 19.8%/month; p < 0.001). Multivariate Cox regression analysis revealed the extent of resection (HR 0.259, p = 0.004), IDH status (HR 3.694, p = 0.012), and tumor spread type (HR = 1.874, p = 0.012) as independent predictors of overall survival (OS). Tumor grade (HR 2.609, p = 0.008), the extent of resection (HR 0.488, p = 0.038), IDH status (HR 2.225, p = 0.025), and tumor spread type (HR 1.531, p = 0.038) were significant in predicting progression‐free survival (PFS).
Conclusion
The current study proposes a classification of the insular glioma according to the tumor spread. It indicates that the tumors defined as type 1 have a relatively better nature and biological characteristics, and those defined as type 3 can be more aggressive and refractory. Besides its predictive value for prognosis, the classification has potential value in formulating surgical strategies for patients with insular gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- China National Clinical Research Center for Neurological Diseases, Beijing, China.
- Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
ORCID-Profile: Bowen Xue, Yazhuo Zhang
Förderung
- the National Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Xue, B., Hou, Z., Deng, Z., Sun, S., Zhang, C., Pan, Y., Zhang, Y., Li, Z., & Xie, J. (2024). Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread. Cancer Medicine. https://doi.org/10.1002/cam4.7377
Vancouver
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, et al. Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread. Cancer Medicine. 2024. doi:10.1002/cam4.7377
BibTeX
@article{Xue2024,
author = {Xue, Bowen and Hou, Zonggang and Deng, Zhenghai and Sun, Shengjun and Zhang, Chuanhao and Pan, Yuesong and Zhang, Yazhuo and Li, Zhenye and Xie, Jian},
title = {Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7377}
}
EUVIMED